Ryan White Care Hepatitis C & B Language
NATAP Webinar:
Friday 12:30pm ET - November 20th, 2026
Register:
Management of Persons Living with HIV Review 2026
Watch Previous NATAP Webinars
Booklet:
ACHIEVING HEALTHY AGING Improving Health Outcomes Over 50
Current HIV Articles and News Updates
HIV
Glasgow:
The Evolution of Integrase Strand Transfer Inhibitors: VH-184, a 3rd-Generation Inhibitor With an Enhanced Resistance Profile
- (11/09/26)
Glasgow:
Comparative Efficacy and Safety of Doravirine/Islatravir versus Contemporary ART Regimens in Virologically Suppressed People Living with HIV-1 at 48 Weeks: A Systematic Review and Network Meta-Analysis
- (11/09/26)
Glasgow:
Patient-Reported Outcomes With Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV-1: Phase 3 Results Through Week 96
- (11/09/26)
Glasgow:
Resistance Analysis at Week 48 of Daily Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Blinded Phase 3 Study in Adults Initiating Treatment for HIV-1
- (11/09/26)
Glasgow:
Evaluation of Weight at Week 48 in a Phase 3 Study in Adults Initiating Treatment for HIV-1 With Doravirine/Islatravir (100 mg/0.25 mg) versus Bictegravir/Emtricitabine/Tenofovir Alafenamide
- (11/09/26)
Glasgow:
Understanding Treatment Experiences with Weekly Oral Islatravir/Lenacapavir in the Phase 3 ISLEND-2 Study: Participant and Provider Interviews
- (11/09/26)
Glasgow:
Quality of Life and Treatment Preference With Weekly ISL/LEN Versus Standard of Care: Week 48 Patient-Reported Outcomes of the Phase 3 ISLEND-2 Study
- (11/09/26)
Glasgow:
Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Standard of Care Across Participant Subgroups Through Week 48 in the Phase 3 ISLEND-2 Trial
- (11/09/26)
Glasgow:
Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults With HIV-1: Week 48 Subgroup Analyses of the Phase 3 ISLEND-1 Trial
- (11/09/26)
Glasgow:
Antiviral Activity, Pharmacokinetics, and Safety of Oral GS-3242 for HIV-1 Treatment
- (11/09/26)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
AASLD:
BULEVIRTIDE MONOTHERAPY PREVENTS LIVER DECOMPENSATION IN HDV-RELATED CIRRHOSIS: 3-YEAR RESULTS FROM A EUROPEAN, RETROSPECTIVE, CONTROLLED COHORT STUDY oral
- (11/08/26)
More Hep D Articles...
Aging & Perinatally Acquired HIV
Glasgow:
Prescription Medication Use, Comorbidity Burden, and Drug-Drug Interaction Potential Among People with HIV in a Large US Claims Database (2024)
- (11/09/26)
Glasgow:
Metabolic and Liver Outcomes Through Week 48 Following Switch to Dolutegravir/Lamivudine in Older, ART-Experienced Adults: The Phase 3b EYEWITNESS Study
- (11/09/26)
More Aging & HIV Articles...
PrEP
Glasgow:
Higher Persistence on Twice-Yearly Lenacapavir Versus Daily F/TDF for PrEP in the UK and France in the PURPOSE 5 Study
- (11/09/26)
Glasgow:
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
- (11/09/26)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
AASLD:
Implementation of a Test-and-Treat Model for HCV Care Using Point-of-Care HCV RNA Testing in La Bodega
- (11/08/26)
AASLD:
Direct-Acting Antiviral Therapy Is Associated With Reduced Cardiovascular, Psychiatric, and Mortality Outcomes in Chronic Hepatitis C: A Propensity Score-Matched Analysis of a Federated Electronic Health Records Network
- (11/08/26)
AASLD:
Absolute Survival Benefit of DAA Therapy in Hospitalized Patients with HCV-Related Cirrhosis: A Restricted Mean Survival Time Analysis (MIMIC-IV
- (11/08/26)
AASLD:
EVALUATING POSTPARTUM LINKAGE TO HEPATITIS C CARE: RESULTS OF A PATIENT OUTREACH STUDY
- (11/08/26)
AASLD:
CASE ASCERTAINMENT RATES FOR CHILDREN INFECTED WITH HEPATITIS C IN FLORIDA Epidemiologic evidence over one decade ยท May 2016-May 2026
- (11/07/26)
AASLD:
Incentivizing Adherence to Improve Outcomes in a Hepatitis C Virus (HCV) Treatment Trial: Results from the Kentucky Viral Hepatitis Treatment (KeY Treat) Study
- (11/07/26)
AASLD:
Evaluating Detection and Outcomes Pre and Post Universal Hepatitis C Screening in Pregnancy Recommendation
- (11/07/26)
AASLD:
SHORTER, FASTER: PATIENT CHARACTERISTICS ASSOCIATED WITH 8- VERSUS 12-WEEK SOFOSBUVIR/VELPATASVIR IN AN INCARCERATED HCV COHORT
- (11/07/26)
AASLD:
COMPARATIVE EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR VERSUS SOFOSBUVIR/VELPATASVIR IN PATIENTS WITH HEPATITIS C: A MULTICENTER PROSPECTIVE STUDY
- (11/07/26)
AASLD:
Real-world impact of drug-drug interactions (DDI): why complex HCV patients are preferentially treated with Sofosbuvir/Velpatasvir (SOF/VEL) over Glecaprevir/Pibrentasvir (GLE/PIB)
- (11/07/26)
AASLD:
Does The Presence of NS5A Resistance-Associated Substitution Significantly Affect The SVR Rate?
- (11/07/26)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
AASLD:
Rates of functional cure in participants with chronic hepatitis B virus infection treated with bepirovirsen: B-Well Phase 3 trials end of study results
- (11/08/26)
AASLD:
Rates of functional cure in participants with chronic hepatitis B virus infection treated with bepirovirsen: B-Well Phase 3 trials end of study results
- (11/08/26)
AASLD:
Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12
- (11/07/26)
AASLD:
Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12
- (11/07/26)
More Hep B Articles...
Fatty Liver, NAFLD, NASH, MASLD, MASH
AASLD:
Updated Early and Week 52 Biomarker (MRI-PDFF, ALT, MRE and PRO-C3) Responses to Resmetirom Associate With Improvements in MASH and Liver Fibrosis
- (11/08/26)
Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study -
- (11/08/26)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
Conference List Here
https://www.croiconference.org/
https://academicmedicaleducation.com/programs/3rd-african-workshop-on-women-and-hiv-2026
https://academicmedicaleducation.com/programs/16th-international-workshop-on-women-and-hiv-2026
https://acthiv.org/
https://ddw.org/?doing_wp_cron=1768748258.8390960693359375000000
https://www.easlcongress.eu/
https://asm.org/events/asm-microbe/home
https://academicmedicaleducation.com/programs/24th-european-meeting-on-hiv-and-hepatitis-2026
https://www.iasociety.org/conferences/aids2026
https://academicmedicaleducation.com/programs?page=2
https://academicmedicaleducation.com/programs/27th-international-workshop-on-clinical-pharmacology-of-hiv-hepatitis-and-other-antiviral-drugs-2026
2026 U.S. Conference on HIV/AIDS
Register to join us from September 17-20, 2026 in Anaheim, CA
Theme - United and Unbreakable: The HIV Movement at 45
https://www.nmac.org/uscha/
https://academicmedicaleducation.com/programs/9th-conference-on-liver-disease-in-africa-colda-2026
https://academicmedicaleducation.com/programs/17th-international-workshop-on-aging-and-hiv-2026
https://idweek.org/
https://aasld-igh.org/Home.aspx https://www.aasld.org/the-liver-meeting
https://hivglasgow.org/
